

ANNOUNCEMENTS | 01.10.2024

Sophie Wang Appointed Chair of the AIPLA Amicus Committee

Sophie Wang, a partner in Choate's Life Sciences and Intellectual Property Litigation groups, has been appointed to serve as Chair of the American Intellectual Property Law Association (AIPLA) Amicus Committee until October 2025.

Sophie was initially appointed by the President of AIPLA to serve as a member of the Amicus Committee in 2020 for a three-year term, and more recently served as Vice Chair. The Amicus Committee identifies cases having significant issues that may impact IP law or practice, considers requests for amicus participation from others pursuant to the committee's rules of procedure, recommends to the Board of Directors that AIPLA file amicus briefs in appropriate situations and obtains authors for such briefs.

Throughout her career, Sophie has represented a number of leading industry organizations at the United States Court of Appeals for the Federal Circuit and the United States Supreme Court in submitting amicus briefs on issues critical to the intellectual property community. In particular, she has represented the Biotechnology Innovation Organization (BIO), the Pharmaceutical Research and Manufacturers of America (PhRMA), the Boston Patent Law Association (BPLA), and the Massachusetts Biotechnology Council (MassBio) in voicing concerns regarding issues such as obviousness-type double patenting, the constitutionality of inter partes reviews, the "blocking patent" doctrine, and the "on-sale bar" doctrine under the AIA and its implications for pharmaceutical and biotech companies. She also submitted an amicus brief on behalf of Sir Gregory Paul Winter and other interested scientists in *Amgen v. Sanofi*, one of the Supreme Court's most highly-watched cases in 2023, concerning the law of enablement as it applies to patents directed to antibody therapeutics. On behalf of AIPLA, Sophie has also submitted two amicus briefs, one in *United States v. Arthrex* concerning the appointment of administrative patent judges, and one recently in *In re: Collect* concerning the doctrine of obviousness-type double patenting.

Sophie's practice focuses on complex patent litigation and trade secrets litigation in federal and state trial and appellate courts, post-grant and inter partes review proceedings before the United States Patent and Trial Appeal Board (PTAB), and contract and licensing disputes within the life sciences and technology industries. She has been named a World's Leading Patent Practitioner by IAM Patent 1000, a Top Woman in Law by Massachusetts Lawyers Weekly, Future Star by Benchmark Litigation, U.S. Intellectual Property Rising Star by LMG Life Sciences, Rising Star by Managing IP Magazine, Massachusetts Super Lawyers Rising Star and a Massachusetts Top Women Rising Star.

Sophie F. Wang

IP Litigation Market Leader